Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms - Martina Colognesi; Daniela Gabbia; Anna Signor; Miles Sarill; Lucia Centofanti; Andrea Rinaldi; Luciano Cascione; Sara Nunziata; Marco Banzato; Andrea Mattarei; Giovanna Finzi; Sonia Sonda; et al. (Repository for Publications and Research Data (ETH Zurich), 2026)
Exported from Psilocybin Research Publication Tracker: https://psilocybin-research.com